BPI21-004: A Qualitative Study Describing Oncology Practitioners’ Approaches to First-Line (1L) Treatment of Metastatic Urothelial Cancer (mUC) in the United States

Authors: Petros Grivas MD, PhD1, Meaghan Roach MPH2, Vivek Pawar PhD3, Caroline Huber MPH2, Suepattra May-Slatter MPH, PhD2, Isha Desai MPH2, Jane Chang MPH4, and Murtuza Bharmal PhD5
View More View Less
  • 1 University of Washington; Seattle Cancer Care Alliance, Fred Hutchinson Cancer Research Center, Seattle, WA
  • | 2 PRECISIONheor, New York, NY
  • | 3 EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts; an affiliate of Merck KGaA, Darmstadt, Germany
  • | 4 Pfizer Inc, New York, NY
  • | 5 EMD Serono, Inc., Rockland, MA, USA; an affiliate of Merck KGaA, Darmstadt, Germany
Restricted access

Corresponding Author: Murtuza Bharmal, PhD
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 293 293 23
PDF Downloads 264 264 24
EPUB Downloads 0 0 0